Welcome to the Starpharma Investor CentreStarpharma Holdings Limited is an Australian stock exchange listed biotechnology company with products based on its dendrimer technology platform. |
![]() |
|
Welcome to the Starpharma Investor CentreStarpharma Holdings Limited is an Australian stock exchange listed biotechnology company with products based on its dendrimer technology platform. |
![]() |
|
Jun 12th, 2024
Starpharma (ASX: SPL, OTCQX: SPHRY) today provides a copy of the DEP® radiotheranostics scientific poster presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in Toronto, Canada, overnight. The scientific poster presents data from Starpharma’s DEP® HER2 radiotheranostics program, demonstrating the promising utility of DEP® dendrimers in precision radiotheranostics for cancer imaging and therapeutic applications.
Read MoreJun 4th, 2024
Starpharma (ASX: SPL, OTCQX: SPHRY) today provides a copy of the DEP® irinotecan presentation delivered at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago, US. The presentation was part of a rapid oral abstract session and highlighted the final results of the DEP® irinotecan Phase 1/2 clinical trial, which were reported in full last week.
Read More
Click here for financial reports archive
Jul 9th, 2024
"Former Novartis exec Cheryl Maley has opened up about her latest career move revealing why she's relocated to lead an ASX-listed biotech after a stellar career in Big Pharma."
Read MoreJun 12th, 2024
Starpharma (ASX: SPL, OTCQX: SPHRY) today provides a copy of the DEP® radiotheranostics scientific poster presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in Toronto, Canada, overnight. The scientific poster presents data from Starpharma’s DEP® HER2 radiotheranostics program, demonstrating the promising utility of DEP® dendrimers in precision radiotheranostics for cancer imaging and therapeutic applications.
Read More